Fig. 2From: Targeting severe symptoms of early 2023-new outbreak of COVID-19 by classical drug dexamethasone: a potential fatality reducing agentResidue Contributions in Binding of Dexamethasone against SARS-CoV-2 RBD. A, SARS RBD differences at amino acid level among different strains. B, Details of the binding pocket and residue of the SARS-CoV-2 RBDs of Wild type, variant Omicron, BJ.1, BM.1.1.1, XBB and XBB.1.5, for DexamethasoneBack to article page